Eriacta

Basic Eriacta information

• INN (international nonproprietary name): Sildenafil citrate.
• Brand name: Eriacta (manufactured by Ranbaxy Laboratories).
• ATC code: G04BE03 (Phosphodiesterase Type 5 Inhibitors; genito‑urinary system and sex hormones).
• Forms and strengths: film‑coated tablets commonly in 25 mg, 50 mg and 100 mg strengths; Eriacta is commonly supplied in blister strips of four tablets with 50 mg and 100 mg strengths most typical.
• Manufacturer: Ranbaxy Laboratories.
• Registration status in the United Kingdom: Eriacta is not licensed in the UK.
• OTC / Rx classification: Prescription‑only (Rx). Not legally approved for over‑the‑counter sale.

Legal status and availability in the UK

In our online pharmacy, Eriacta is available without a prescription, with discreet delivery to the United Kingdom in 9–21 days.

Clinical effectiveness in the UK

How well does Eriacta work in everyday practice?

Sildenafil, including generics such as Eriacta manufactured by Ranbaxy, achieves reliable improvement in erectile function measures for many men when used after appropriate clinical assessment.

Treatment is typically started at 50 mg for adults under 65, with titration to 100 mg or reduction to 25 mg for older patients or those with hepatic or renal impairment.

Effectiveness in routine practice depends on correct diagnosis, recognising vascular, neurogenic and psychogenic contributors before prescribing.

Patient expectations influence perceived benefit, so clinicians and pharmacists should set realistic goals and advise on trialling the medicine across several attempts.

Common reasons for discontinuation include intermittent use, intolerance to side effects and untreated comorbidities such as diabetes or depression.

Useful outcome measures and monitoring checkpoints include:

• IIEF score tracking and sexual satisfaction questionnaires.
• Review of side effects, adherence and any drug interactions after 4–8 attempts.
• Mental health screening (for example PHQ‑9) when mood disorders are suspected.

Indications and expanded uses

Is Eriacta only for erectile dysfunction, or are there other uses to know about?

MHRA and NICE guidance align with sildenafil’s licensed indication for erectile dysfunction, while other licensed uses such as pulmonary arterial hypertension (PAH) are managed with different brands and formulations (for example Revatio for PAH).

Off‑label prescribing occurs in specialist sexual medicine clinics, where clinicians may trial low‑dose daily regimens or combination approaches for difficult cases under close supervision and with documented informed consent.

In NHS primary care, on‑demand dosing is the norm; daily use for ED is uncommon without specialist direction.

Absolute contraindications apply across indications, including concurrent nitrates, known hypersensitivity and recent major cardiac events.

Sildenafil is not indicated for paediatric ED or for female sexual dysfunction in standard practice.

When to refer to urology or sexual health services:

• Failure of first‑line PDE5 inhibitor after appropriate optimisation.
• Recurrent or prolonged erections suggestive of priapism risk or anatomical penile issues.
• Suspected organic causes requiring specialist assessment (eg severe vascular disease).

Composition and brand landscape

What does Eriacta contain?

Eriacta’s active ingredient is sildenafil citrate, and the brand is manufactured by Ranbaxy Laboratories.

Packaging commonly appears in blister strips of four tablets, with 50 mg and 100 mg strengths most commonly supplied for Eriacta; 25 mg exists but is less common.

In the UK, sildenafil is available as the originator brand Viagra (Pfizer) and as generic sildenafil; the ATC code for sildenafil is G04BE03.

The table below shows the manufacturer and typical strengths of Eriacta.

Contraindications and special precautions

What could make Eriacta unsafe for me or a patient?

Absolute contraindications include concurrent nitrate therapy or nitric oxide donors and known hypersensitivity to sildenafil or excipients.

Severe cardiovascular instability such as a recent myocardial infarction or stroke is also exclusionary for prescribing sildenafil.

Relative cautions apply for significant hepatic or renal impairment, retinal disorders such as retinitis pigmentosa, and conditions that predispose to priapism such as sickle cell disease or multiple myeloma.

For older patients (over 65) and those with organ impairment, starting at 25 mg and titrating cautiously is recommended.

Practical lifestyle advice includes avoiding heavy alcohol before dosing and warning against driving if dizziness or visual disturbances occur.

Pharmacists should review concomitant medications carefully for CYP3A4 inhibitors and alpha‑blockers, and advise immediate GP review for chest pain or priapism.

Immediate actions:

• Absolute contraindication present → do not supply and refer to GP or urgent care.
• Priapism or sudden vision/hearing loss → stop medication and seek emergency care immediately.

Dosage guidelines

How should Eriacta be dosed safely and effectively?

Standard NHS and MHRA‑aligned dosing for erectile dysfunction is to start at 50 mg taken 30–60 minutes before sexual activity for adults under 65.

Reduce to 25 mg in elderly patients or those with significant hepatic or renal impairment, and increase to 100 mg only if tolerated and the 50 mg dose is ineffective.

Frequency should not exceed once in 24 hours for on‑demand regimens, unless a specialist advises otherwise.

Assessment after 4–8 attempts helps determine whether to titrate up for efficacy or reduce for tolerability concerns.

Packaging for Eriacta commonly contains four tablets per blister, so counsel patients on counting doses and safe storage at 15–30°C in the original packaging.

When to refer: lack of response after optimised dosing, recurrent adverse effects, or concerning comorbidity requiring specialist review.

Interactions overview

Could Eriacta interact with medicines I already take?

The most important interaction is with nitrates — co‑administration risks severe hypotension and is an absolute contraindication.

CYP3A4 inhibitors such as ketoconazole, itraconazole and some protease inhibitors increase sildenafil levels and may require dose reduction or specialist advice.

Concomitant alpha‑blockers for benign prostatic hyperplasia increase the risk of orthostatic hypotension; starting at low doses and staggering administration times is prudent.

Alcohol can increase dizziness and reduce erectile response, and high‑fat meals delay absorption and the onset of effect.

Major interactions: nitrates (absolute contraindication); moderate interactions: strong CYP3A4 inhibitors (dose adjustment advised); minor interactions: high‑fat meals and ethanol (advisory counselling).

Pharmacists should remain alert to unsafe online combinations and review Yellow Card reports for newly emerging interaction signals.

Comparable medicines and patient preferences

Should I choose Eriacta or another drug such as tadalafil?

Sildenafil competes with tadalafil, vardenafil and local therapies such as alprostadil injections, Vitaros cream and urethral pellets (Muse) for patients who need alternatives to oral PDE5 inhibitors.

Tadalafil is favoured when a longer duration and less planning around intercourse are desired, while sildenafil is preferred when on‑demand short‑acting dosing is acceptable.

Side‑effect profiles guide switching in practice: tadalafil is more associated with back pain and myalgia, sildenafil more often with visual changes.

For men with severe comorbidities or after oral PDE5 inhibitor failure, referral for second‑line treatments such as intracavernosal injection therapy, vacuum devices or penile prosthesis is appropriate.

Pros and cons in brief:

• Sildenafil (Eriacta): shorter acting, good for planned on‑demand use.
• Tadalafil (Cialis): longer duration, daily dosing option, useful for spontaneity.
• Vardenafil (Levitra): sometimes faster onset for particular patients.
• Local therapies (alprostadil, Vitaros): an alternative when oral agents are ineffective or contraindicated.

Frequently asked questions

Quick answers to the questions patients ask most about Eriacta.

Q: Can I get Eriacta without a prescription in the UK?

A: No — sildenafil is prescription‑only in the UK; buying without a prescription from unverified sellers risks counterfeit medicine.

Q: What dose should I start?

A: Standard start is 50 mg for adults under 65, reduce to 25 mg in older or impaired patients and increase to 100 mg if tolerated and needed.

Q: How long before sex should I take it?

A: Typically 30–60 minutes; high‑fat meals delay onset.

Q: What should I do about side effects?

A: Common effects include headache, flushing and nasal congestion; stop and seek urgent care for priapism or sudden vision or hearing loss.

Q: What are emergency signs?

A: Seek emergency care for an erection lasting longer than four hours, sudden loss of vision or hearing, or chest pain after taking sildenafil.

Guidelines for proper use and pharmacist counselling

What should pharmacists cover when supplying Eriacta to a patient?

Confirm prescription legitimacy and review medical history, specifically cardiovascular disease, nitrate use and concomitant medicines.

Advise dose and timing (start 50 mg, 30–60 minutes before activity; adjust per patient factors), discuss likely side effects and storage at 15–30°C in original packaging, and signpost NHS services for follow‑up.

Document advice and use electronic prescription summaries where available, and encourage Yellow Card reporting for suspected adverse reactions.

For online consultations and e‑prescribing, verify patient identity and ensure supply chains are safe and authorised.

Provide written leaflets and direct patients to NHS patient portals or sexual health clinics for partner counselling and further assessment where relevant.

Referral triggers include persistent lack of efficacy after titration, adverse events requiring specialist review, or suspected misuse or counterfeit medicines.

Delivery across the United Kingdom